HomeNewsGlobal Pharma

Skyhawk Gets Australian Regulatory Approval to Extend SKY-0515 Treatment Duration

Skyhawk Gets Australian Regulatory Approval to Extend SKY-0515 Treatment Duration

Skyhawk Therapeutics has announced that the Australian Human Research Ethics Committees (HREC) have approved SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Huntington's Disease (HD).

HREC also agreed to the inclusion of Volumetric MRI (vMRI) measurements as an early exploratory endpoint in the trial. vMRI measurement of the brain's regions affected in HD can provide additional data on SKY-0515's effect in HD patients.

"We're excited to announce that after demonstrating 72 percent huntingtin (HTT) mRNA reduction with SKY-0515 in the healthy volunteer portion of this study, we have been approved to extend the duration of treatment in Huntington's patients," said Sergey Paushkin, Head of R&D, Skyhawk Therapeutics.

"We're thankful to the HREC for their careful review of our data and approval of this extension, as well as their approval of our use of vMRI measurements as an exploratory endpoint. Both approvals broaden our opportunity to demonstrate the performance of SKY-0515 and may enable us to progress to pivotal trials faster than previously expected," added Paushkin.

SKY-0515 is Skyhawk's investigational, oral small molecule RNA splicing modifier developed through the company's novel RNA-splicing platform. SKY-0515 is designed to reduce both HTT protein and PMS1 protein, a key driver of somatic CAG-repeat expansion and HD pathology.

SKY-0515 is currently being evaluated in a Phase 1 clinical trial. The Phase 1 clinical trial is a first-in-human trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKY-0515 in healthy volunteers and individuals with early-stage Huntington's disease (HD). The trial is separated into three parts.

Topline pharmacodynamic results for Parts A (single-ascending dose) and B (multiple-ascending dose), which evaluated SKY-0515 in healthy volunteers, demonstrated a dose-dependent reduction of HTT mRNA and reached an average reduction of 72 percent at a daily oral dose of 9mg. SKY-0515 was generally well tolerated at all doses tested.

Part C is a double-blind placebo-controlled parallel design study of two dose levels of SKY-0515 and placebo in individuals with early-stage HD, which aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic parameters. Recruitment for Part C is ongoing, and topline data are expected in mid-2025.

More news about: global pharma | Published by Aishwarya | December - 11 - 2024

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members